follow
immun
respons
two
type
differenti
b
cell
persist
memori
pool
plasma
cell
confer
immedi
protect
secret
specif
antibodi
memori
b
cell
confer
rapid
enhanc
respons
secondari
challeng
review
recent
advanc
understand
heterogen
dynam
persist
human
memori
b
cell
plasma
cell
well
new
method
isol
human
monoclon
antibodi
find
offer
new
insight
human
b
cell
respons
relev
vaccin
therapeut
intervent
well
establish
cours
celldepend
b
cell
respons
b
cell
prolifer
differenti
memori
b
cell
longliv
plasma
cell
use
highli
purifi
human
b
cell
shown
optim
expans
differenti
class
switch
requir
addit
bcr
trigger
cell
help
third
signal
deliv
tlr
agonist
cytokin
produc
activ
dendrit
cell
find
consist
mous
experi
address
requir
tlr
express
b
cell
certain
type
tdepend
respons
polysaccharid
behav
cellindepend
antigen
activ
b
cell
crosslink
bcr
polysaccharid
vaccin
avail
decad
provid
shortterm
protect
thought
unabl
gener
b
cell
memori
shown
vaccin
polysaccharid
lead
eventu
exhaust
antigenspecif
b
cell
contrast
proteinpolysaccharid
conjug
vaccin
elicit
tdepend
respons
long
last
memori
least
adult
concept
memori
b
cell
deriv
celldepend
respons
recent
challeng
find
mice
cellindepend
type
ii
respons
bacteri
polysaccharid
lead
expans
memori
b
cell
distinct
lo
lo
phenotyp
activ
memori
b
cell
strongli
suppress
igg
antibodi
find
may
explain
hyperigm
syndrom
patient
lack
aid
longev
remain
key
aspect
immunolog
memori
appli
plasma
cell
memori
b
cell
recent
longitudin
studi
shown
antivir
serum
antibodi
induc
infect
vaccin
live
virus
stabl
halfliv
rang
year
antibodi
induc
protein
vaccin
halfliv
year
longev
plasma
cell
determin
extrins
factor
collect
defin
surviv
nich
contrast
adult
vaccin
vaccin
earli
childhood
lead
sustain
serum
antibodi
level
mous
model
failur
attribut
defect
capac
bone
marrow
stromal
cell
produc
april
requir
mainten
longliv
plasma
cell
better
definit
mechan
control
plasma
cell
surviv
requir
order
improv
vaccin
earli
life
human
memori
b
cell
recircul
blood
main
reservoir
repres
lymphoid
tissu
bone
marrow
spleen
surviv
requir
remain
defin
mous
studi
indic
bli
requir
mainten
b
cell
april
mainten
plasma
cell
ligand
appear
dispens
surviv
memori
b
cell
condit
delet
gene
deplet
memori
b
cell
abrog
secondari
antibodi
respons
evid
steadyst
condit
human
memori
b
cell
slowli
divid
suggest
memori
b
cell
pool
may
maintain
homeostat
prolifer
case
memori
cell
view
support
observ
memori
b
cell
highli
respons
polyclon
stimuli
present
b
memori
stem
cell
identifi
remain
matter
specul
lack
function
sap
lead
human
mice
b
cell
defici
character
defect
germin
center
format
lack
b
cell
memori
use
twophoton
intravit
imag
shown
sap
defici
select
impair
abil
cell
stabli
interact
cognat
b
cell
thu
prevent
deliveri
effect
cell
help
requir
germin
center
memori
format
subset
memori
b
cell
plasma
cell
defin
basi
express
surfac
marker
although
wide
use
marker
memori
b
cell
substanti
fraction
bona
fide
memori
b
cell
lack
express
b
cell
mistakenli
taken
cell
fact
gener
confus
field
transport
express
exclus
human
matur
naiv
b
cell
immatur
activ
memori
b
cell
includ
lack
human
constitut
tlr
express
characterist
memori
b
cell
thu
explain
capac
former
readili
respond
tlr
agonist
absenc
bcr
stimul
inhibitori
receptor
express
uniqu
popul
human
memori
b
cell
resid
epitheli
tissu
character
distinct
transcript
protein
profil
recent
similar
popul
tissuelik
memori
b
cell
lo
lo
identifi
blood
hivvirem
individu
cell
exhaust
phenotyp
sinc
express
multipl
inhibitori
receptor
prolifer
poorli
stimul
vitro
strikingli
hivspecif
respons
enrich
exhaust
b
cell
wherea
influenzaspecif
respons
enrich
function
memori
b
cell
data
suggest
hivassoci
exhaust
b
cell
may
contribut
poor
antibodi
respons
hiv
infect
individu
subset
negativememori
b
cell
lack
describ
healthi
donor
increas
frequenc
sle
patient
subset
circul
plasma
blast
plasma
cell
identifi
use
surfac
marker
steadyst
condit
larg
fraction
circul
plasma
blast
express
iga
guthom
molecul
consist
mucos
origin
newli
form
plasma
blast
express
hladr
plasma
cell
displac
bone
marrow
lack
marker
human
larg
fraction
circul
b
cell
igm
hi
igd
lo
carri
somat
mutat
ig
gene
cell
initi
consid
igm
memori
b
cell
subsequ
studi
indic
repres
distinct
popul
relat
mous
margin
zone
mz
b
cell
although
share
mani
properti
mous
counterpart
respons
bacteri
polysaccharid
human
mz
b
cell
display
strike
differ
presenc
somat
mutat
capac
recircul
human
mz
b
cell
develop
progress
first
two
year
life
explain
unrespons
infant
polysaccharid
vaccin
furthermor
time
bcr
repertoir
undergo
somat
diversif
occur
absenc
antigendriven
respons
clearli
demonstr
find
develop
mz
b
cell
polyclon
profil
spectratyp
oppos
bona
fide
memori
b
cell
display
oligoclon
profil
rel
littl
inform
dynam
mz
b
cell
respons
howev
one
case
analyz
shown
particular
clonotyp
detect
low
frequenc
blood
antigen
challeng
alreadi
mutat
stage
follow
vaccin
polysaccharid
vaccin
clone
found
expand
igm
igg
plasma
cell
spleen
still
detect
blood
four
week
later
mz
b
cell
clearli
distinct
bona
fide
igm
memori
b
cell
gener
tdepend
respons
igm
hi
found
peripher
blood
normal
individu
low
frequenc
total
b
cell
higher
frequenc
aiddefici
patient
studi
outlin
first
time
human
antigenindepend
mechan
diversif
preimmun
repertoir
origin
describ
bird
sheep
diversif
occur
postrearrang
process
gene
convers
somat
hypermut
evid
process
cellindepend
shown
presenc
mutat
mz
b
cell
patient
lack
well
analysi
rag
gc
nude
mice
reconstitut
human
hematopoiet
stem
cell
addit
recent
shown
unlik
b
cell
human
transit
b
cell
respond
cpg
differenti
mzlike
b
cell
find
suggest
possibl
bcr
diversif
might
initi
transit
b
cell
bacteri
dna
microbi
product
present
mucos
surfac
strike
human
select
mutat
antibodi
protect
encapsul
bacteria
possibl
reason
may
mutat
antibodi
produc
human
mz
b
cell
superior
natur
nonmut
polyreact
igm
antibodi
besid
role
antibodi
product
bacteri
polysaccharid
possibl
mz
b
cell
may
involv
type
immun
respons
inde
mous
mz
b
cell
shown
play
protect
role
host
defens
influenza
viru
recent
isol
human
monoclon
antibodi
neutral
influenza
virus
phage
librari
prepar
human
mz
b
cell
would
consist
possibl
upon
booster
immun
memori
b
cell
expand
rapidli
gener
burst
plasma
cell
peak
day
peripher
blood
time
point
number
circul
plasma
cell
exceed
baselin
level
increas
account
primarili
antigenspecif
plasma
cell
plasma
cell
burst
coincid
sharp
increas
serum
antibodi
reach
plateau
level
day
indic
vast
major
plasma
cell
gener
shortliv
recent
studi
show
contrast
wide
held
belief
plasma
cell
gener
respons
new
influenza
vaccin
higher
affin
vaccin
previous
encount
viru
suggest
human
origin
antigen
sin
compromis
immedi
respons
influenza
vaccin
coincid
gener
antigenspecif
hladr
plasma
blast
popul
plasma
cell
appear
blood
larg
number
latter
cell
secret
antibodi
unknown
specif
repres
longliv
plasma
cell
displac
nich
bone
marrow
lost
capac
home
back
bound
die
result
consist
novel
model
newli
gener
old
plasma
cell
compet
limit
number
surviv
nich
recent
mous
studi
reveal
yet
anoth
mechan
turn
longliv
plasma
cell
mediat
igg
contain
immun
complex
trigger
apoptosi
bone
marrow
plasma
cell
engag
fcgriib
simpl
method
clonal
analysi
memori
b
cell
develop
use
total
pbmc
stimul
agonist
use
method
shown
follow
booster
immun
kinet
antigenspecif
b
cell
delay
compar
plasma
cell
reach
peak
two
week
declin
period
sever
week
expans
specif
b
cell
strike
peak
valu
reach
total
memori
b
cell
multipl
parallel
assay
perform
clonal
cultur
supernat
use
monitor
fine
specif
crossreact
antibodi
produc
memori
b
cell
particular
shown
small
fraction
virusspecif
antibodi
neutral
activ
autoreact
b
cell
form
consequ
random
ig
gene
recombin
remov
two
checkpoint
matur
b
cell
virtual
absent
mz
b
cell
surprisingli
howev
selfreact
antibodi
includ
antinuclear
antibodi
frequent
express
igg
memori
b
cell
healthi
donor
antibodi
creat
de
novo
somat
hypermut
transit
matur
naiv
igg
memori
b
cell
find
consist
previou
report
show
highli
specif
antihiv
antibodi
also
polyreact
remain
establish
whether
extent
autoreact
b
cell
differenti
plasma
cell
possibl
autoreact
b
cell
might
anerg
mechan
exist
prevent
termin
differenti
long
recogn
singl
antibodi
bind
multipl
unrel
antigen
multispecif
often
refer
crossreact
degeneraci
promiscu
offer
mean
expand
repertoir
size
provid
comprehens
coverag
antigen
univers
achiev
via
differ
mechan
rang
rigid
recognit
ident
residu
display
differ
ligand
conform
divers
antibodi
allow
bind
structur
distinct
ligand
differenti
posit
ligand
differ
subsit
paratop
recent
therapeut
monoclon
antibodi
engin
express
two
specif
vegf
screen
random
librari
antibodi
author
abl
select
sever
variant
clone
bound
vegf
clone
lost
reactiv
other
retain
reactiv
thu
behav
twoinon
antibodi
tempt
specul
select
process
similar
use
isol
twoinon
antibodi
may
occur
natur
whenev
memori
b
cell
confront
new
antigen
last
year
b
cell
plasma
cell
deplet
provid
new
opportun
treatment
malign
autoimmun
diseas
antibodi
rituximab
target
b
cell
plasma
cell
approv
treatment
b
cell
lymphoma
rheumatoid
arthriti
use
treat
chronic
lymphocyt
leukemia
autoimmun
diseas
mediat
autoreact
antibodi
system
lupu
erythematosu
sle
pemphigu
therapeut
effect
observ
also
patient
relapsingremit
multipl
sclerosi
provid
support
role
b
cell
antibodi
diseas
mechan
kinet
b
cell
deplet
rituximab
studi
mice
express
human
effici
b
cell
deplet
shown
depend
number
factor
includ
microenviron
extent
b
cell
recircul
express
fc
receptor
complement
regulatori
protein
consist
anim
data
patient
express
high
affin
allel
fcgriiia
better
prognost
outcom
rituximab
treatment
compar
patient
express
low
affin
allel
combinatori
therapi
consid
increas
effect
fresh
plasma
antibodi
addit
new
antibodi
develop
enhanc
capac
induc
adcc
fix
complement
autoimmun
diseas
longliv
plasma
cell
secret
autoantibodi
repres
yet
unmet
therapeut
challeng
resist
convent
treatment
immunosuppress
antibodi
howev
immunoabl
use
antithymocyt
serum
follow
autolog
stem
cell
transplant
shown
effect
deplet
longliv
plasma
cell
induc
longterm
remiss
patient
sever
autoimmun
diseas
owe
high
rate
protein
synthesi
limit
proteolyt
capac
plasma
cell
hypersensit
proteasom
inhibitor
bortezomib
drug
approv
treatment
multipl
myeloma
elimin
shortliv
longliv
autoreact
plasma
cell
activ
termin
unfold
protein
respons
studi
murin
model
b
cell
deplet
provid
relev
insight
dynam
b
cell
plasma
cell
popul
two
recent
studi
examin
plasma
cell
level
mice
treat
antibodi
conclud
longliv
plasma
cell
pool
maintain
despit
matur
memori
b
cell
deplet
least
period
week
interestingli
one
studi
author
abl
deplet
bone
marrow
plasma
cell
vivo
administr
antibodi
found
condit
memori
b
cell
requir
repopul
bone
marrow
plasma
cell
abil
memori
b
cell
reconstitut
bone
marrow
plasma
cell
pool
would
consist
contribut
memori
b
cell
homeostasi
plasma
cell
serum
antibodi
level
last
five
year
sever
method
report
retriev
monoclon
antibodi
human
memori
b
cell
plasma
cell
much
impetu
studi
deriv
need
develop
antibodi
effect
neutral
human
pathogen
broadli
neutral
antibodi
could
use
therapeut
also
tool
design
vaccin
capabl
elicit
broadli
neutral
respons
improv
method
ebv
immort
use
isol
memori
b
cell
infect
patient
monoclon
antibodi
potent
broadli
neutral
sar
coronaviru
avian
influenza
viru
advantag
method
antibodi
produc
immort
b
cell
directli
test
use
function
assay
viral
neutral
therefor
precis
knowledg
antigen
target
requir
anoth
advantag
relat
longev
memori
b
cell
best
exemplifi
isol
survivor
influenza
pandem
monoclon
antibodi
potent
neutral
influenza
viru
use
differ
approach
analyz
whole
spectrum
memori
b
cell
antigenbind
memori
b
cell
isol
cell
sort
ig
gene
clone
singl
cell
pcr
donor
b
cell
memori
repertoir
specif
compos
independ
clone
express
high
affin
antibodi
differ
epitop
specif
surprisingli
although
donor
broadli
neutral
serum
antibodi
none
antibodi
isol
properti
find
rais
possibl
breadth
neutral
depend
larg
number
antibodi
target
hiv
variant
altern
possibl
bait
use
suitabl
select
b
cell
broad
specif
repertoir
memori
b
cell
might
differ
plasma
cell
produc
serum
antibodi
altern
sourc
human
monoclon
antibodi
repres
circul
plasma
blast
bone
marrow
plasma
cell
plasma
blast
isol
seven
day
boost
highli
enrich
antigenspecif
cell
ig
gene
rescu
singl
cell
pcr
approach
led
isol
antibodi
rh
blood
group
antigen
tetanu
toxoid
influenza
viru
consid
plasma
cell
memori
b
cell
differ
kinet
interest
establish
whether
antibodi
isol
sourc
may
differ
properti
term
load
somat
mutat
fine
specif
mous
shown
plasma
cell
emerg
germin
center
memori
b
cell
higher
level
somat
mutat
novel
approach
discuss
complement
wellestablish
method
phage
display
librari
method
recent
use
isol
antibodi
capabl
neutral
differ
subtyp
influenza
viru
vitro
vivo
antibodi
use
region
inhibit
fusion
bind
conserv
site
stalk
region
hemagglutinin
contact
residu
provid
present
clear
whether
antibodi
made
cours
immun
respons
influenza
conclus
studi
human
memori
b
cell
respons
continu
provid
relev
inform
rapidli
translat
new
therapi
autoimmun
infecti
diseas
